This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soini, Y. Articles by Pääkkö, P. Search for Related Content PubMed PubMed Citation Articles by Soini, Y. Articles by Pääkkö, P.

Apoptosis and Expression of Apoptosis Regulating Proteins bcl-2, mcl-1, bcl-X, and bax in Malignant Mesothelioma¹

Departments of Pathology and Internal Medicine, University of Oulu and Oulu University Hospital, FIN-90401 Oulu, Finland, and Occupational Health Institute, Helsinki, Finland

We investigated apoptosis and the expression of bcl-2, mcl-1, bcl-X, and bax in histological sections from 35 malignant mesotheliomas and 21 metastatic adenocarcinomas. Moreover, the expression of bcl-2, mcl-1, bcl-X, and bax were assessed by Western blotting in nonmalignant human mesothelial cells (Met5A) and seven malignant cell lines. The apoptotic index in mesotheliomas was 1.07 ± 1.14%. Patients with mesotheliomas showing a high apoptotic index (0.75%) had a worse prognosis (P = 0.008). bcl-2 positivity was observed in only seven cases, but bcl-X, mcl-1, and bax positivity was seen in all of them. In immunoblotting experiments, all mesothelioma cell lines were negative for bcl-2 but positive for bcl-X, mcl-1, and bax. The apoptotic index in bcl-2-negative mesotheliomas was 1.25 ± 1.24% and in bcl-2-positive ones, 0.47 ± 0.42% (P = 0.014). The apoptotic index did not significantly associate with bcl-X, mcl-1, or bax expression (P = 0.19, P = 0.25, and P = 0.46, respectively). No significant difference was observed in apoptosis or expression of bcl-2, bcl-X, or bax between malignant mesotheliomas and metastatic adenocarcinomas. The former, however, showed more often weak mcl-1 immunoreactivity (P = 0.01). The results show that the extent of apoptosis may influence patient prognosis. bcl-2 is inversely associated with the apoptotic index but is relatively infrequently expressed in malignant mesotheliomas. Widespread expression of bcl-X, mcl-1, and bax suggests that these proteins may also take part in apoptosis regulation in mesotheliomas.

This article has been cited by other articles:

				K. S. Abayasiriwardana, D. Barbone, K.-U. Kim, C. Vivo, K. K. Lee, T. B. Dansen, A. E. Hunt, G. I. Evan, and V. C. Broaddus Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim Mol. Cancer Ther., October 1, 2007; 6(10): 2766 - 2776. [Abstract] [Full Text] [PDF]

				P. Cacciotti, D. Barbone, C. Porta, D. A. Altomare, J. R. Testa, L. Mutti, and G. Gaudino SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure Cancer Res., June 15, 2005; 65(12): 5256 - 5262. [Abstract] [Full Text] [PDF]

				M. K. Ozvaran, X. X. Cao, S. D. Miller, B. A. Monia, W. K. Hong, and W. R. Smythe Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma Mol. Cancer Ther., May 1, 2004; 3(5): 545 - 550. [Abstract] [Full Text] [PDF]

				S. Singhal, R. Wiewrodt, L. D. Malden, K. M. Amin, K. Matzie, J. Friedberg, J. C. Kucharczuk, L. A. Litzky, S. W. Johnson, L. R. Kaiser, et al. Gene Expression Profiling of Malignant Mesothelioma Clin. Cancer Res., August 1, 2003; 9(8): 3080 - 3097. [Abstract] [Full Text] [PDF]

				W. R. Smythe, I. Mohuiddin, M. Ozveran, and X. X. Cao Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product J. Thorac. Cardiovasc. Surg., June 1, 2002; 123(6): 1191 - 1198. [Abstract] [Full Text] [PDF]

				X. X. Cao, I. Mohuiddin, F. Ece, D. J. McConkey, and W. R. Smythe Histone Deacetylase Inhibitor Downregulation of bcl-xl Gene Expression Leads to Apoptotic Cell Death in Mesothelioma Am. J. Respir. Cell Mol. Biol., November 1, 2001; 25(5): 562 - 568. [Abstract] [Full Text] [PDF]